ST6GAL1 and neoplasm: ST6Gal1, the enzyme that catalyzes tumor-associated α2,6-sialylation, has been consistently elevated across GI tumors and favors stemness properties, including increased CSC surface markers, enhanced spheroid growth, and the upregulation of stemness-associated transcription factors such as Sox9 and Slug [7,40].